Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study.

J Clin Med · 2025 · PMC12347298 · PMID 40807220

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Poor performance status (PS) was associated with a trend toward inferior OS, though the difference did not reach statistical significance (PS 0–2: median OS 11.1 months, 95% CI 3.9–18.0 vs.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.